Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Lydia Wunderle, MD, Susanne Badura, Fabian Lang, MD, Andrea Wolf, Eberhard Schleyer, MD, Hubert Serve, MD, Nicola Goekbuget, MD, Heike Pfeifer, MD, Gesine Bug, MD, PhD, Oliver G. Ottmann, MD

Blood (2013) 122 (21): 2675.

https://doi.org/10.1182/blood.V122.21.2675.2675

Published: 2013

Journal Articles

Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study.

Frank P. Kroschinsky, MD, Kai Friedrichsen, Juliane Mueller, MD, Mathias Haenel, MD, Gerhard Ehninger, Eberhard Schleyer, MD

Blood (2006) 108 (11): 4662.

https://doi.org/10.1182/blood.V108.11.4662.4662

Published: 2006

Journal Articles

Plasma Concentrations and AUC of Pegfilgrastim Have No Impact on Its Efficacy in Peripheral Blood Progenitor Cell Mobilization.

Frank P. Kroschinsky, MD, Eberhard Schleyer, MD, Kristina Hoelig, MD, Uta Oelschlaegel, PhD, Rainer Ordemann, MD, Kirsten Poppe-Thiede, MD, Markus A. Schaich, MD, Claudia Rutt, MD, Gerhard Ehninger, MD

Blood (2005) 106 (11): 5321.

https://doi.org/10.1182/blood.V106.11.5321.5321

Published: 2005

Journal Articles

Single-Dose Pegfilgrastim after Chemotherapy Is Highly Effective in Enhancing the Mobilization of Autologous CD34+ Peripheral Blood Stem Cells in Patients with Lymphoid Malignancies and Solid Tumors.

Frank Kroschinsky, MD, Kristina Hoelig, MD, Uwe Platzbecker, MD, Eberhard Schleyer, MD, Rainer Ordemann, MD, Astrid Haack, Markus Schaich, MD, Martin Bornhaeuser, MD, Gerhard Ehninger, MD

Blood (2004) 104 (11): 2922.

https://doi.org/10.1182/blood.V104.11.2922.2922

Published: 2004

Journal Articles

Feasibility and Efficacy of Peripheral Blood Progenitor Cell Mobilisation with Pegfilgrastim for Allogeneic Stem Cell Transplantation.

Frank Kroschinsky, MD, Kristina Hoelig, MD, Rainer Ordemann, MD, Astrid Haack, Kirsten Poppe-Thiede, MD, Matthias Blechschmidt, MD, Gabi Rall, Martin Bornhaeuser, MD, Eberhard Schleyer, MD, Claudia Rutt, Gerhard Ehninger, MD

Blood (2004) 104 (11): 5003.

https://doi.org/10.1182/blood.V104.11.5003.5003

Published: 2004

Journal Articles

Rapamycin Has Biological Activity in a Subset of Patients with Myelodysplastic Syndrome - Results of a Phase I/II Trial.

Uwe Platzbecker, MD, Michael Haase, MD, Regina Herbst, MD, Anette Hanel, MD, Karsten Voigtmann, Christian Thiede, MD, Brigitte Mohr, MD, Eberhard Schleyer, MD, Traugott Leopold, MD, Mathias Hanel, MD, Gerhard Ehninger, MD, Martin Bornhauser, MD

Blood (2004) 104 (11): 1449.

https://doi.org/10.1182/blood.V104.11.1449.1449

Published: 2004

NARROW

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study.

Plasma Concentrations and AUC of Pegfilgrastim Have No Impact on Its Efficacy in Peripheral Blood Progenitor Cell Mobilization.

Single-Dose Pegfilgrastim after Chemotherapy Is Highly Effective in Enhancing the Mobilization of Autologous CD34+ Peripheral Blood Stem Cells in Patients with Lymphoid Malignancies and Solid Tumors.

Feasibility and Efficacy of Peripheral Blood Progenitor Cell Mobilisation with Pegfilgrastim for Allogeneic Stem Cell Transplantation.

Rapamycin Has Biological Activity in a Subset of Patients with Myelodysplastic Syndrome - Results of a Phase I/II Trial.

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study.

Plasma Concentrations and AUC of Pegfilgrastim Have No Impact on Its Efficacy in Peripheral Blood Progenitor Cell Mobilization.

Single-Dose Pegfilgrastim after Chemotherapy Is Highly Effective in Enhancing the Mobilization of Autologous CD34+ Peripheral Blood Stem Cells in Patients with Lymphoid Malignancies and Solid Tumors.

Feasibility and Efficacy of Peripheral Blood Progenitor Cell Mobilisation with Pegfilgrastim for Allogeneic Stem Cell Transplantation.

Rapamycin Has Biological Activity in a Subset of Patients with Myelodysplastic Syndrome - Results of a Phase I/II Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only